Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade

Elevance Health, Inc. (NYSE:ELV) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Elevance Health, Inc. (NYSE:ELV) has a ‘Buy’ or equivalent rating from slightly more than half of the analysts covering the stock. With a median price target of $394, the stock has an upside potential of 19.12%.

On November 26, TD Cowen increased the price target on Elevance Health, Inc. (NYSE:ELV) to $400.00 from $380.00, with an unchanged ‘Buy’ rating on the stock, naming it as its “Best Idea for 2026.” The firm raised concerns regarding managed care, describing it as a “complicated investment landscape.” TD Cowen noted that the company’s current 2026 EPS consensus estimate is appropriate and supports growth, with the firm increasing its 2026 EPS estimate to $27.25.

Healthcare Careers That Require a Master’s Degree

Dragon Images/Shutterstock.com

Earlier on November 4, Mizuho trimmed its price target on Elevance Health, Inc. (NYSE:ELV) to $400 from $420, while keeping an ‘Outperform’ rating on the stock. The firm also reduced 2026 and 2027 earnings guidance to better reflect added challenges in Carelon.

Elevance Health, Inc. (NYSE:ELV) is an Indiana-based health benefits company operating through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. Founded in 2001, the company is dedicated to simplifying the healthcare system.

While we acknowledge the potential of ELV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ELV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.